Acesion Pharma ApS

Address: Nordre Fasanvej 215

Sponsor Overview

assignment

Specializations

Cardiac Arrhythmia Management

The sponsor concentrates on developing therapeutic interventions for cardiac rhythm disorders, with particular emphasis on atrial fibrillation treatment. Research efforts are directed toward pharmacological solutions that address abnormal heart rhythm patterns and restore normal cardiac electrical activity.

Atrial Fibrillation Therapeutics
Antiarrhythmic Drug Development
Cardiac Rhythm Restoration

The clinical development program focuses on novel approaches to managing supraventricular arrhythmias, seeking to provide effective pharmacological options for patients experiencing irregular heartbeat conditions. This work addresses a significant unmet medical need in cardiovascular medicine.

Cardiovascular Electrophysiology

Investigation into the electrical properties of the heart forms a core area of therapeutic interest, with research centered on understanding and modulating cardiac conduction systems. The sponsor's portfolio reflects commitment to advancing treatments that influence myocardial electrical activity and improve cardiac function.

Cardiac Ion Channel Modulation
Electrical Cardioversion Alternatives
Atrial Electrophysiology

Development activities target mechanisms that regulate cardiac depolarization and repolarization, aiming to restore and maintain normal sinus rhythm through innovative pharmacological interventions designed for optimal cardiac electrical stability.

Acute Cardiovascular Interventions

The therapeutic pipeline includes solutions for acute cardiac events requiring immediate intervention, specifically targeting conditions where rapid restoration of normal heart function is critical. Research encompasses acute arrhythmia management strategies that can be implemented in emergency and hospital settings.

Rapid Rhythm Conversion
Emergency Cardiac Care
Hospital-Based Arrhythmia Treatment

Focus areas include developing treatments suitable for recent-onset atrial fibrillation and other acute rhythm disturbances, providing clinicians with effective pharmacological tools for time-sensitive cardiovascular emergencies.

Trial Name	Country	Status
A Randomized, Controlled, First-in-Human Study of AP31969 on Single and Multiple Ascending Doses and Food Effect in Healthy Subjects with Atrial Fibrillation	The Netherlands	Not Recruiting
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.	Bulgaria Denmark Germany Hungary Italy Poland The Netherlands	Recruiting